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Abstract Homocysteine is known to be a risk factor for several
vascular diseases. Previously, we found a significant association
between plasma homocysteine and plasma extracellular-super-
oxide dismutase (EC-SOD) levels. The binding of EC-SOD to
human and bovine aortic endothelial cell cultures showed
significant decreases after incubation with 10 WM homocysteine,
whereas the expression of EC-SOD in fibroblast cell cultures was
inhibited with a high concentration (1 mM) of homocysteine.
Furthermore, binding of EC-SOD to heparin immobilized on
plates was decreased with homocysteine. These observations
suggested that homocysteine decreases the binding of EC-SOD
to vascular endothelial cell surfaces by degradation of endo-
thelial heparan sulfate proteoglycan, which results in a loss of
the ability to protect endothelial cell surfaces from oxidative
stress. ß 2000 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Modest elevation of plasma homocysteine, commonly re-
ferred to as hyperhomocysteinemia, is generally considered
to be a risk factor for coronary, cerebral and peripheral vas-
cular disease [1^4] and thrombosis [5]. While the mechanisms
mediating vascular changes are still unclear, there is evidence
that elevated plasma homocysteine may cause endothelial cell
injury or dysfunction [6,7], inhibition of endothelium-depen-
dent relaxation [8,9], vascular thrombosis [10,11], smooth
muscle cell proliferation [12], oxidative stress [13^15] and
may a¡ect endothelial cell gene expression [14,16^18].
Extracellular-superoxide dismutase (EC-SOD) is a secretory
glycoprotein with an a⁄nity for heparin-like substances
[19,20]. The plasma EC-SOD level might a¡ect the physiolog-
ical and pathological conditions of the vascular system since
this enzyme is the principal enzymatic scavenger of superoxide
in the extracellular space and is present in the circulation in
equilibrium between the plasma phase and the glycosamino-
glycans on the endothelium [21,22]. In previous studies, we
showed that the plasma EC-SOD levels were elevated in pa-
tients with renal diseases [23] but reduced in patients with a
history of myocardial infarction [24].
Recently, we reported that there was a signi¢cant positive
relationship between plasma homocysteine and plasma EC-
SOD levels in patients with homocysteinuria [25], but the
mechanism responsible for this e¡ect remains unclear. We
hypothesized that homocysteine causes degradation of endo-
thelial cell function, followed by detachment of EC-SOD from
the endothelium and elevation of plasma EC-SOD. The
present study was designed to elucidate the mechanism by
which homocysteine increased the plasma EC-SOD level and
modulated endothelial cell function.
2. Materials and methods
2.1. Reagents
DL-homocysteine and heparin^bovine serum albumin (BSA) com-
plex were purchased from Sigma (St Louis, MO, USA). Human re-
combinant EC-SOD (r-EC-SOD), prepared as described previously
[20], was kindly provided by Symbicom AB (Umeafi, Sweden). Mouse
anti-r-EC-SOD monoclonal antibody was prepared as described pre-
viously [26]. Alkaline phosphatase-coupled rabbit anti-mouse IgG
antibody was purchased from Zymed Laboratories Inc. (San Francis-
co, CA, USA). Bradford reagent was obtained from Bio-Rad Labo-
ratories (Hercules, CA, USA). Dulbecco’s modi¢ed Eagle’s medium
(DMEM) was obtained from Nissui Pharmaceutical Co. (Tokyo, Ja-
pan). Bovine aortic endothelial (BAE) cells, human aortic endothelial
(HAE) cells and CS-C complete medium were purchased from Dai-
nippon Pharmaceutical Co. Ltd. (Osaka, Japan). Immunoplates were
purchased from Nunc (Roskilde, Denmark).
2.2. EC-SOD production of ¢broblast cells
Human skin ¢broblast cell lines obtained from healthy volunteers
were suspended in DMEM containing 10% (v/v) fetal calf serum
(FCS) and cultured in 96-well plates, as described previously [27].
When the cells were grown to near con£uence, the medium was re-
placed with fresh DMEM containing 0.5% (v/v) FCS followed by
culture for 24 h. After the medium was replaced again, various con-
centrations of homocysteine were added and followed by incubation
in a CO2 incubator (37‡C, 5% CO2) for 24 h. Conditioned medium
was harvested and EC-SOD in the medium was measured by ELISA
[28].
2.3. Binding of EC-SOD to endothelial and ¢broblast cells
BAE cells and ¢broblast cells were suspended in DMEM containing
10% (v/v) FCS and cultured in 96-well plates or 35-mm tissue culture
dishes as described previously [27]. HAE cells were cultured in 96-well
plates containing CS-C complete medium supplemented with 100
U/ml penicillin and 100 Wg/ml streptomycin. When endothelial cells
and ¢broblast cells were near con£uent, the media were replaced with
fresh DMEM containing 0.5% (v/v) FCS and cultured for 24 h. The
medium was replaced again, and various concentrations of homocys-
teine were added followed by incubation in a CO2 incubator for 24 h.
The cell layers were rinsed with medium, and r-EC-SOD dissolved in
the same medium was added followed by incubation at 4‡C for 1 h.
At the end of the incubation period, the unbound r-EC-SOD was
collected and the cells were washed twice with phosphate-bu¡ered
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saline (PBS). The cells were then incubated at 4‡C for 30 min with 10
mg/ml of heparin dissolved in the same medium to remove the cell-
surface-bound r-EC-SOD, which was then quanti¢ed by ELISA [28].
2.4. Binding of EC-SOD to immobilized heparin
Binding of r-EC-SOD to immobilized heparin was performed essen-
tially by the method of Najjam, et al. [29] but with slight modi¢ca-
tions. Brie£y, immunoplate wells were coated with 100 Wl of 50 mM
Tris^HCl, pH 7.4, containing 12.7 mM EDTA and 0.4 Wg/ml heparin^
BSA complex and left to stand overnight at 4‡C. Each well was
washed three times with PBS containing 0.05% (v/v) Tween 20
(PBS^Tween), blocked with PBS^Tween containing 1% (w/v) BSA,
and the plates were then left to stand overnight at 4‡C.
A volume of 100 Wl of the various concentrations of homocysteine
diluted in DMEM containing 0.5% (v/v) FCS was added to each of
the wells and the plates were kept for 24 h in a CO2 incubator. The
wells were then rinsed once with DMEM containing 0.5% (v/v) FCS
and incubated for 3 h with r-EC-SOD diluted in the same medium.
Wells were washed three times with PBS^Tween, and bound EC-SOD
was then determined by ELISA [28].
2.5. Statistical analysis
The data shown are the means þ S.D. of four to six separate experi-
ments. Statistical signi¢cance was estimated using the Student’s t-test,
and a value of P6 0.05 was considered to be statistically signi¢cant.
3. Results
3.1. E¡ects of homocysteine on EC-SOD expression in human
skin ¢broblasts
EC-SOD is expressed in several human cell types, including
¢broblast cells [30]. As shown in Fig. 1, EC-SOD release by
human skin ¢broblasts was signi¢cantly inhibited by the treat-
ment with a high concentration of homocysteine (1 mM), but
not with low concentrations of reagents (10 and 100 WM).
3.2. E¡ects of homocysteine on r-EC-SOD binding to the
endothelial and ¢broblast cells
Previous studies showed that homocysteine inhibited thymi-
dine incorporation into human umbilical vein endothelial cells
[12]. In the present study, treatment with homocysteine for 24
h did not show this cytotoxic e¡ect on BAE or HAE cells
(data not shown).
It is known that EC-SOD is mainly expressed by ¢broblast
cells and smooth muscle cells in vascular walls [30^32], and
that this enzyme can bind on cultured anchorage-dependent
cell lines including endothelial cells [22]. When 2.5 ng/well r-
EC-SOD was added to a 96-well plate coated with HAE or
BAE cells, the binding of the enzyme to endothelial cells
(380 þ 26 ng/mg HAE cell protein and 267 þ 84 ng/mg BAE
cell protein) was observed. We next assessed whether homo-
cysteine a¡ects the binding of EC-SOD to the endothelial
cells. As shown in Fig. 2, the amount of r-EC-SOD bound
to the endothelial cells surface was signi¢cantly (P6 0.001 for
HAE and P = 0.040 for BAE cells) decreased by pretreatment
with 10 WM homocysteine for 24 h. At 1 mM homocysteine,
the binding of r-EC-SOD to HAE and BAE cell surfaces was
reduced to 70.9% (P = 0.0015) and 73.8% (P = 0.0017), of the
respective control values. On the other hand, r-EC-SOD
slightly bound also on ¢broblast cells (68 þ 20 ng/mg ¢bro-
blast cell protein). The extent of EC-SOD binding to ¢bro-
blasts was signi¢cantly (P6 0.001) less than that to endothe-
lial cells. The amount of r-EC-SOD bound to the ¢broblast
Fig. 1. E¡ects of homocysteine on EC-SOD expression. Human
skin ¢broblasts were incubated with various concentrations (0, 0.01,
0.1 and 1 mM) of homocysteine (Hcy) for 24 h. The amounts of
EC-SOD in conditioned media were determined by ELISA. Data
represent the means þ S.D. of four experiments. *P6 0.05 vs. con-
trol.
Fig. 2. Inhibition of EC-SOD binding to endothelial cells by homo-
cysteine. HAE (A) and BAE (B) cells were incubated with various
concentrations (0, 0.01, 0.1 and 1 mM) of homocysteine (Hcy) for
24 h, followed by addition of r-EC-SOD as described in Section 2.
The amounts of bound r-EC-SOD were determined by ELISA and
expressed as a percentage of control value. Data represent the
means þ S.D. of six experiments. *P6 0.05, **P6 0.001 vs. control.
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cells tended to decrease by pretreatment with 1 mM homo-
cysteine, but not signi¢cantly (84.4% of control, P = 0.0594).
It has been reported that homocysteine induces endothelial
cell injury due to copper-catalyzed generation of hydrogen
peroxide [6,33]. To con¢rm whether this is due to a decrease
of r-EC-SOD-binding to the endothelial cell surface, endothe-
lial cells were incubated with or without copper ions. Addition
of copper or homocysteine resulted in signi¢cant decreases in
r-EC-SOD binding to HAE and BAE cell surfaces (Fig. 3).
Furthermore, pretreatment of BAE cells with both homocys-
teine and copper signi¢cantly inhibited r-EC-SOD binding
compared to those with homocysteine only (P = 0.0092) and
copper only (P = 0.0077). In HAE cells, its e¡ect was approx-
imately the same as that of homocysteine or copper only.
3.3. E¡ects of homocysteine on r-EC-SOD binding to
immobilized heparin
An immobilized heparin^BSA plate was incubated with var-
ious concentrations of homocysteine for 24 h. The amount of
r-EC-SOD binding to immobilized heparin was signi¢cantly
and concentration-dependently decreased by pretreatment
with homocysteine (Fig. 4). At a concentration of 0.2 mM, the r-EC-SOD-binding was reduced to 84.1% of the control
(P = 0.0136), and at 1 mM homocysteine, binding was reduced
to 50.1% (P6 0.0001).
4. Discussion
It has been reported that homocysteine a¡ects gene expres-
sion of antioxidant enzymes and protein in human vascular
endothelial cells [16,17]. Recently, we reported that there was
a signi¢cant correlation between plasma homocysteine and
EC-SOD levels [25,34]. Therefore, we examined how homo-
cysteine changes EC-SOD level in plasma. The aim of this
study was two-fold: ¢rst, to determine the e¡ect of homocys-
teine on EC-SOD release by ¢broblast cells ; second, the e¡ect
of homocysteine on EC-SOD-binding to endothelial cells.
However, EC-SOD release by ¢broblasts was not a¡ected
with 10 and 100 WM homocysteine, and was inhibited only
at high concentration (1 mM). It has been reported that EC-
SOD is mainly expressed by ¢broblasts and smooth muscle
cells and that it is located throughout the vascular wall, with
signi¢cant amounts observed in all layers, adventitia, sur-
rounding smooth muscle cells and endothelium [30^32]. This
enzyme might slowly di¡use in the vascular wall and become
distributed according to the a⁄nity of glycosaminoglycans.
On the other hand, EC-SOD in the vascular system apparent-
ly forms an equilibrium between the plasma phase and endo-
thelial cell surface, and EC-SOD on the endothelial cell sur-
face should provide an e⁄cient protection for vessel walls.
There is evidence that elevated plasma homocysteine may
cause endothelial cell injury [6,7]. We hypothesized that ho-
mocysteine decreased the binding of EC-SOD to endothelial
cell surfaces, and this result led to a signi¢cant correlation
between plasma homocysteine and EC-SOD levels. In this
report, we showed that homocysteine-treated endothelial cells
lost r-EC-SOD binding activity, and a concentration-depen-
dent decrease was seen in BAE cells. In several studies, the
presence of both homocysteine and copper has been shown to
cause cell injury, dysfunction, inhibition of cell growth
[6,13,17] and mitochondrial damage of endothelial cells [14].
Furthermore, inhibition of antithrombin III binding to the
endothelial cell surface by homocysteine has been suggested
Fig. 3. E¡ects of copper on homocysteine-induced decrease of EC-
SOD binding to endothelial cells. HAE (A) and BAE (B) cells were
incubated in the absence or presence of 1 mM of homocysteine
(Hcy) or 10 WM of copper ion (CuCl2) for 24 h, followed by addi-
tion of r-EC-SOD. The amounts of bound r-EC-SOD were deter-
mined by ELISA and expressed as a percentage of control value.
Data represent the means þ S.D. of six experiments. *P6 0.05 vs.
control, #P6 0.01 vs. Hcy (3) and copper ion (+), VP6 0.01 vs.
Hcy (+) and copper ion (3).
Fig. 4. Inhibition of EC-SOD binding to immobilized heparin by
homocysteine. Heparin^BSA-coated plates were incubated with vari-
ous concentrations of homocysteine (Hcy) for 24 h and r-EC-SOD
was then added. The amounts of bound r-EC-SOD were determined
as described in Section 2 and expressed as a percentage of con-
trol value. Data represent the means þ S.D. of ¢ve experiments.
*P6 0.05, **P6 0.001 vs. control.
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to be due to the production of hydrogen peroxide [11]. We
also observed the e¡ects of homocysteine and copper on the
binding of EC-SOD to BAE cells in this study. However,
there were no morphological changes in BAE or HAE cells
that were treated with homocysteine for 24 h (data not
shown). Therefore, we speculated that homocysteine induces
heparan sulfate proteoglycan dysfunction and decreases EC-
SOD-binding to endothelial cells. It was found that binding of
r-EC-SOD to immobilized heparin is markedly decreased by
homocysteine treatment. The detailed mechanism by which
homocysteine causes heparin dysfunction is not yet clear.
Nitric oxide (NO) is produced by a variety of cells in the
vascular system. NO is produced constitutively and contrib-
utes to the modulation of vasomotor tone and to inhibition of
platelet and leukocyte aggregation and adhesion to the endo-
thelium, properties that have been shown to be anti-athero-
genic. NO reacts extremely rapidly with superoxide to pro-
duce peroxynitrite, a potential mediator of oxidant-induced
cellular injury. Peroxynitrite is a potent oxidant, capable of
oxidizing thiols [35] and DNA bases [36], and of causing ty-
rosine nitration [37] and initiating lipid peroxidation [38]. It is
possible that EC-SOD in the vascular system di¡uses into the
extracellular space and scavenges superoxide before it reacts
with NO. Elimination of EC-SOD from the endothelium may
result in the elevation of superoxide, which would then pro-
duce highly reactive peroxynitrite. Therefore, our results sug-
gested that homocysteine decreases the ability to scavenge
superoxide and indirectly causes injury of the vascular endo-
thelium. Recently, it has been reported that homocysteine in-
creases the superoxide production in porcine aortic endothe-
lial cells [8], and vascular EC-SOD activity is substantially
reduced in patients with coronary artery disease [39]. In-
creased superoxide levels caused by homocysteine and reduced
EC-SOD activity may contribute to an imbalance in produc-
tion and elimination of superoxide, which would result in oxi-
dative stress in endothelial cells.
In conclusion, our study demonstrated that binding of EC-
SOD to endothelial cell surfaces was signi¢cantly decreased by
pretreatment with a low concentration of homocysteine,
which might have been due to the dysfunction of heparan
sulfate proteoglycan on the cells. Moreover, EC-SOD release
by ¢broblasts was also decreased by incubation with high
concentration of homocysteine. While further studies are
needed to explore these mechanisms, these ¢ndings suggest
that homocysteine may decrease the protection of vascular
endothelial cell surfaces from superoxide anions and result
in the pathogenesis of atherosclerosis and cardiovascular dis-
ease.
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